Eirion Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Eirion Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Eirion Therapeutics: 7 sponsored US clinical trials, none currently recruiting.
Eirion Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glabellar Lines, with 1 trials.
Upper-quartile sponsor footprint
Eirion Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
A Study to Evaluate AI-09 In Participants With Glabellar Lines
NCT07321834
AI-09 In Subjects With Glabellar Lines, GL-101
NCT05565950
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
NCT04985916
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
NCT03912805
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
NCT03839693
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
NCT03655691
ET-01 in Subjects With Lateral Canthal Lines
NCT03326856
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
Therapeutic Areas
How the Eirion Therapeutics early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Glabellar Lines (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Eirion Therapeutics: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Eirion Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Eirion Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Eirion Therapeutics or any single study.
- None of Eirion Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Glabellar Lines is the condition Eirion Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glabellar Lines trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eirion Therapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.